Ionis Pharmaceuticals, Inc.
IONS
$55.31
-$0.72-1.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -40.73% | 86.98% | -10.26% | 17.12% | 100.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -40.73% | 86.98% | -10.26% | 17.12% | 100.69% |
| Cost of Revenue | -2.46% | 5.41% | 15.35% | -0.34% | -5.40% |
| Gross Profit | -75.13% | 146.64% | -270.53% | 27.17% | 24,439.26% |
| SG&A Expenses | 65.35% | 97.19% | 47.81% | 57.06% | 49.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -18.18% | -- | -- | -- | -- |
| Total Operating Expenses | 18.58% | 30.54% | 23.83% | 12.19% | 7.17% |
| Operating Income | -173.16% | 20.04% | -93.51% | -7.75% | 311.55% |
| Income Before Tax | -191.78% | 37.13% | -112.93% | 10.90% | 286.60% |
| Income Tax Expenses | 6,420.00% | 87.93% | 154.94% | 105.88% | -131.25% |
| Earnings from Continuing Operations | -192.79% | 37.03% | -119.83% | 8.45% | 286.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -192.79% | 37.03% | -119.83% | 8.45% | 286.45% |
| EBIT | -173.16% | 20.04% | -93.51% | -7.75% | 311.55% |
| EBITDA | -168.80% | 21.23% | -94.74% | -7.98% | 326.46% |
| EPS Basic | -189.27% | 39.38% | -114.42% | 14.85% | 271.01% |
| Normalized Basic EPS | -169.99% | 23.54% | -98.23% | -1.56% | 307.64% |
| EPS Diluted | -199.01% | 39.38% | -114.42% | 14.85% | 254.19% |
| Normalized Diluted EPS | -180.19% | 23.54% | -98.23% | -1.56% | 281.22% |
| Average Basic Shares Outstanding | 3.95% | 3.87% | 2.53% | 7.52% | 9.03% |
| Average Diluted Shares Outstanding | -9.28% | 3.87% | 2.53% | 7.52% | 24.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |